Wave Life Sciences recently joined PPMD for a community webinar to provide an update on the company’s Phase 2 FORWARD-53 trial of WVE-N531, Wave’s exon skipping oligonucleotide being investigated for the treatment of individuals with Duchenne who are amenable to exon 53 skipping. Wave discussed the recently released FORWARD-53 data and answered questions from the community.

Disclaimer: This webinar program is intended solely to provide information to the public. The views and opinions expressed as part of this webinar program do not necessarily state or reflect those of Parent Project Muscular Dystrophy (PPMD).